Liraglutide vs Tirzepatide
A side-by-side research comparison of Liraglutide and Tirzepatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Liraglutide | Tirzepatide |
|---|---|---|
| Full name | Liraglutide (GLP-1 Receptor Agonist / Saxenda) | Tirzepatide (Dual GIP/GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | FDA Approved | FDA Approved |
| Mechanism | Binds and activates the GLP-1 receptor, enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite through hypothalamic signaling. | Activates both GIP and GLP-1 receptors simultaneously for synergistic effects on insulin secretion, appetite reduction, and fat metabolism. GIP activation enhances fat oxidation and energy expenditure. |
| Molecular weight | 3,751 Da | 4,814 Da |
| Half-life | 13 hours | 5 days (120 hours) |
| Bioavailability | ~55% (subcutaneous) | High (SubQ ~80%) |
| Typical dose | 0.6-3.0 mg | 2.5 mg → titrate up to 15 mg |
| Frequency | Once daily | Once weekly |
| Route | Subcutaneous | Subcutaneous injection |
Liraglutide reported benefits
- Proven weight loss (5-10%)
- Long safety track record
- Cardiovascular benefit
- Improved glycemic control
- Reduced food intake
Tirzepatide reported benefits
- Superior weight loss (20-25%)
- Excellent glycemic control
- Reduced triglycerides
- Lower blood pressure
- Improved insulin sensitivity
- Potential MASH benefits
Related comparisons
Research and educational reference only. Not medical advice.